Trials / Completed
CompletedNCT00731627
Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 803 (actual)
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Intracranial bleeding from ruptured blood vessels (called a subarachnoid haemorrhage -SAH) affects 7000 patients each year in the UK and is a source of considerable death and disability, even in young adults. Recent observations indicate that these bleeds can cause reduced cerebral blood flow which leads to a bad outcome. High rates of death and disability occur, and are particularly prevalent when low cerebral blood flow results in stroke. Prevention of cerebral artery spasm and improvement in blood vessel reflexes are the target of modern therapy. Candidate drugs include statins which have an impeccable safety record and multiple potential beneficial actions (improve cerebral blood flow, reduce inflammatory processes, reduce adverse blood coagulation) following SAH. The investigators plan to use a statin, Simvastatin (40 mg) to improve cerebral blood flow and reduce inflammation. We have already completed a phase 11 study (n=80) which demonstrated potential benefits for acute statin therapy following SAH, and the investigators now wish to conduct a multi-centre phase 111 study to explore any potential clinical benefits in a larger population (n=1600). The purpose is to see whether the positive effects of statins seen in our phase II study translate into clinical benefits - both short term (e.g. reduced need for intensive care) and long term (outcome and wellbeing at 6 months).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | one tablet a day for up to 21 days |
| DRUG | simvastatin | simvastatin 40mg once a day for a maximum of 21 days |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2013-09-01
- Completion
- 2014-02-01
- First posted
- 2008-08-11
- Last updated
- 2014-06-25
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00731627. Inclusion in this directory is not an endorsement.